Tempus AI (NASDAQ:TEM) reported second-quarter revenue growth of 22% and raised its full-year outlook, citing accelerating ...
Pfizer's non-COVID commercial portfolio is accelerating, with new launches and business development products growing 22% to a nearly $12 billion annualized run rate. Seagen's oncology portfolio ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results